Optimization of the k2′ Parameter Estimation for the Pharmacokinetic Modeling of Dynamic PIB PET Scans Using SRTM2
暂无分享,去创建一个
R. Boellaard | P. D. De Deyn | D. Peretti | D. Vállez García | F. Reesink | B. D. de Jong | R. Dierckx | J. Doorduin | P. D. de Deyn
[1] B. Långström,et al. The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.
[2] Alexander Hammers,et al. Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.
[3] Richard E Carson,et al. Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] C. Weiller,et al. Assessment of Striatal Dopamine D2/D3 Receptor Availability with PET and 18F-Desmethoxyfallypride: Comparison of Imaging Protocols Suited for Clinical Routine , 2012, The Journal of Nuclear Medicine.
[5] Richard E Carson,et al. Tracer Kinetic Modeling of [11C]AFM, a New PET Imaging Agent for the Serotonin Transporter , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[7] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[8] Nelleke Tolboom,et al. Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.
[9] M. Hüll,et al. Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.
[10] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[11] O. Lopez,et al. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study , 2012, Acta Neuropathologica.
[12] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[13] Karl J. Friston,et al. Unified segmentation , 2005, NeuroImage.
[14] D. Selkoe,et al. DIFFUSE SENILE PLAQUES: THE CAUDATE AND PUTAMEN AS A MODEL , 1989 .
[15] J. Morris,et al. Current concepts in mild cognitive impairment. , 2001, Archives of neurology.
[16] G. V. Van Hoesen,et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.
[17] R. Boellaard,et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies , 2019, PloS one.
[18] R. Boellaard,et al. Parametric Imaging of [11C]Flumazenil Binding in the Rat Brain , 2017, Molecular Imaging and Biology.
[19] Yun Zhou,et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.
[20] Richard E Carson,et al. Kinetic Modeling of the Serotonin 5-HT1B Receptor Radioligand [11C]P943 in Humans , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] Oscar L Lopez,et al. Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET , 2015, The Journal of Nuclear Medicine.
[23] R. Boellaard,et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[24] S. Hirai,et al. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.
[25] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[26] Ove Almkvist,et al. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[27] Christine M Sandiego,et al. Reference Region Modeling Approaches for Amphetamine Challenge Studies with [11C]FLB 457 and PET , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] Osama Sabri,et al. Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol , 2017, The Journal of Nuclear Medicine.
[29] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[30] Chris Buckley,et al. Parametric imaging and quantitative analysis of the PET amyloid ligand [18F]flutemetamol , 2015, NeuroImage.
[31] Ronald Boellaard,et al. Quantification of [18F]florbetapir: A test–retest tracer kinetic modelling study , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[32] A. Lammertsma,et al. Forward to the Past: The Case for Quantitative PET Imaging , 2017, The Journal of Nuclear Medicine.
[33] R. Boellaard,et al. Parametric Binding Images of the TSPO Ligand 18F-DPA-714 , 2016, The Journal of Nuclear Medicine.
[34] M. Mattson. Pathways towards and away from Alzheimer's disease , 2004, Nature.
[35] A. Hammers,et al. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease , 2016 .
[36] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[37] C. Rowe,et al. Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.
[38] L. Ferrucci,et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.
[39] R. Boellaard,et al. Parametric Imaging of [ 11 C ] Flumazenil Binding in the Rat Brain , 2017 .